424 S. Bethlehem Pike
Ft. Washington, PA 19034
Tel: 216-619-8650
Fax: 215-283-6005


Founded: 2004

Officers : Rick Sannem, Partner; Peter Kenney, Partner; Patty Henhoeffer, Managing Director; Elyse Cole, Vice President, Strategy and Strategic Services; Bill Fay, Director, Client Services; Abby Galardi, Director, Creative Services; Nicole Landau, Director, Finance

2012 Gross Income: $10 million to $15 million.

Full Time Employees: 49 (2012) 41 (2011)

Healthcare Accounts: Alcon Canada: Vitalux; McNeil Consumer Healthcare: TYLENOL, Children's TYLENOL, Children's Motrin; McNeil Nutritionals: SPLENDA, NECTRESSE, Lactaid; OraPharma: Arestin; Wellspring: Emetrol, Dyrenium; Biomers; Bausch & Lomb; Imodium; NuPathe

Number of Accounts gained: 8

Account gained: OraPharma: EZ White; WellSpring: Gelusil, VisionSource/SmileSource Monistat Endocyte Lansinoh Similisan

Services: Strategy: Research, Analytics and Measurement Planning: Brand Positioning, Trends and Marketing Creative: Print, Video, Digital, Mobile Apps, Social Media

Featured Work

Description: > Kids’ Wellness Tracker is a new app that makes it easy for parents to track children’s height, weight, vaccines, symptoms, and medicines, and get dosing for Children’s TYLENOL® and Children’s MOTRIN® products. This free children’s health tracker is available on the App StoreSM.

Creative/account team: Account: Stephanie DiLucchio, Account Supervisor Strategy: Rick Sannem, Partner; Jennifer Threlfall, Strategist Creative: Charlie Brown, Creative Director; Jason Slomack, Creative Director; Eileen Mesi, Associate Creative Director Technical: Quinn Hall, Tech Lead Production: Danielle Zavada, Sr. Project Manager

Why this product is special: Kids’ Wellness Tracker, from the makers of Children’s TYLENOL® and Children’s MOTRIN®, is an all-in-one solution that combines both trackers and tools to help parents manage children’s health. The app has been downloaded over 12,000 times and is currently ranked #15 among the top 100 Free Medical Apps.

Medicate responsibly, urges maker of Tylenol

J&J's campaign picks up where the FDA left off when it alerted physicians to concerns about prescribing acetaminophen-containing drugs but deferred action relative to OTC products.

Email Newsletters